Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Mayne, Janice ^a   Ooi, Teik Chye ^b,c   Raymond, Angela ^a   Cousins, Marion ^b   Bernier, Lise ^d   Dewpura, Thilina ^a   Sirois, Francine ^c   Mbikay, Majambu ^c   Davignon, Jean ^d   Chrétien, Michel ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Compound heterozygotes; Hypercholesterolemia; Hypocholesterolemia; Low density lipoprotein receptor; PCSK9; Single nucleotide polymorphisms

Indexed keywords

CHOLESTANOL; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROTEIN VARIANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AFRICAN CANADIAN; AGED; ARTICLE; CAUCASIAN; CAUCASIAN CANADIAN; CHOLESTEROL BLOOD LEVEL; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FAMILY STUDY; GENE FREQUENCY; GENE SEQUENCE; HUMAN; LOSS OF FUNCTION MUTATION; PROTEIN BLOOD LEVEL; RACE; RACE DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

AFRICAN CONTINENTAL ANCESTRY GROUP; CANADA; CHOLESTEROL; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84877245019     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-70     Document Type: Article

References (43)

1. Lipoproteins and atherosclerosis. Babiak J, Rudel LL, Baillieres Clin Endocrinol Metab 1987 1 3 515 550 10.1016/S0950-351X(87)80022-8 3330421
2. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Austin MA, Hutter CM, Zimmern RL, Humphries SE, Am J Epidemiol 2004 160 5 407 420 10.1093/aje/kwh236 15321837 (Pubitemid 39166973)
3. A receptor-mediated pathway for cholesterol homeostasis. Brown MS, Goldstein JL, Science 1986 232 4746 34 47 10.1126/science.3513311 3513311 (Pubitemid 16037973)
4. The proprotein convertases are potential targets in the treatment of dyslipidemia. Seidah NG, Prat A, J Mol Med 2007 85 7 685 696 10.1007/s00109-007-0172-7 17351764 (Pubitemid 47063524)
5. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Varret M, Rabes JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, Devillers M, Krempf M, Coulon M, Thiart R, Am J Hum Genet 1999 64 5 1378 1387 10.1086/302370 10205269 (Pubitemid 30468756)
6. [PCSK9, from gene to protein: a new actor involved in cholesterol homeostasis]. Abifadel M, Rabes JP, Boileau C, Varret M, Med Sci (Paris) 2006 22 11 916 918 10.1051/medsci/20062211916
7. Proprotein convertases as therapeutic targets. Chretien M, Seidah NG, Basak A, Mbikay M, Expert Opin Ther Targets 2008 12 10 1289 1300 10.1517/14728222.12.10.1289 18781827
8. The biology and therapeutic targeting of the proprotein convertases. Seidah NG, Prat A, Nat Rev Drug Discov 2012 11 5 367 383 10.1038/nrd3699 22679642
9. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M, Proc Natl Acad Sci USA 2003 100 3 928 933 10.1073/pnas.0335507100 12552133 (Pubitemid 36183932)
10. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, J Biol Chem 2004 279 47 48865 48875 10.1074/jbc.M409699200 15358785 (Pubitemid 39625767)
11. Moonlighting proteins-an update. Jeffery CJ, Mol Biosyst 2009 5 4 345 350 10.1039/b900658n 19396370
12. Moonlighting proteins. Jeffery CJ, Trends Biochem Sci 1999 24 1 8 11 10.1016/S0968-0004(98)01335-8 10087914 (Pubitemid 29074455)
13. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD, J Clin Invest 2006 116 11 2995 3005 10.1172/JCI29383 17080197 (Pubitemid 44684484)
14. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, Nat Struct Mol Biol 2007 14 5 413 419 10.1038/nsmb1235 17435765 (Pubitemid 46685885)
15. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, McPherson PS, Attie AD, Prat A, Seidah NG, Traffic 2007 8 6 718 732 10.1111/j.1600-0854.2007.00562.x 17461796 (Pubitemid 46785153)
16. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, J Lipid Res 2007 48 7 1488 1498 10.1194/jlr.M700071-JLR200 17449864 (Pubitemid 47312011)
17. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH, J Biol Chem 2007 282 25 18602 18612 10.1074/jbc.M702027200 17452316 (Pubitemid 47100234)
18. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, Cummings RT, Calzetta A, Cubbon RM, Fischer PA, J Biol Chem 2007 282 28 20502 20512 10.1074/jbc.M701634200 17493938 (Pubitemid 47100016)
19. Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, Lemaire P, Duke G, Miao B, Duclos F, J Biol Chem 2010 285 52 40965 40978 10.1074/jbc.M110.154815 20937814
20. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor. Holla OL, Laerdahl JK, Strom TB, Tveten K, Cameron J, Berge KE, Leren TP, Biochem Biophys Res Commun 2011 406 2 234 238 10.1016/j.bbrc.2011.02.023 21324305
21. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. Surdo PL, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfi A, EMBO Rep 2011 12 12 1300 1305 10.1038/embor.2011.205 22081141
22. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Nat Genet 2003 34 2 154 156 10.1038/ng1161 12730697 (Pubitemid 36666925)
23. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, Shattuck DM, Hum Genet 2004 114 4 349 353 10.1007/s00439-003-1071-9 14727179 (Pubitemid 38324948)
24. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, Marais AD, Van Heyningen C, Soutar AK, Arterioscler Thromb Vasc Biol 2005 25 12 2654 2660 10.1161/01.ATV.0000190668.94752.ab 16224054 (Pubitemid 43732293)
25. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. Evans D, Beil FU, BMC Med Genet 2006 7 66 10.1186/1471-2350-7-66 16875509 (Pubitemid 44376992)
26. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, Hum Mutat 2005 26 5 497 10.1002/humu.9383 16211558
27. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Berge KE, Ose L, Leren TP, Arterioscler Thromb Vasc Biol 2006 26 5 1094 1100 10.1161/01.ATV.0000204337.81286.1c 16424354 (Pubitemid 43732117)
28. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH, Nat Genet 2005 37 2 161 165 10.1038/ng1509 15654334
29. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Fasano T, Cefalu AB, Di Leo E, Noto D, Pollaccia D, Bocchi L, Valenti V, Bonardi R, Guardamagna O, Averna M, Arterioscler Thromb Vasc Biol 2007 27 3 677 681 10.1161/01.ATV.0000255311.26383. 2f 17170371
30. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH, Am J Hum Genet 2006 78 3 410 422 10.1086/500615 16465619 (Pubitemid 43291224)
31. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Miyake Y, Kimura R, Kokubo Y, Okayama A, Tomoike H, Yamamura T, Miyata T, Atherosclerosis 2008 196 1 29 36 10.1016/j. atherosclerosis.2006.12.035 17316651
32. The c.43-44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Yue P, Averna M, Lin X, Schonfeld G, Hum Mutat 2006 27 5 460 466 10.1002/humu.20316 16619215 (Pubitemid 43673333)
33. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH, N Engl J Med 2006 354 12 1264 1272 10.1056/NEJMoa054013 16554528
34. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C, Hum Mutat 2009 30 4 520 529 10.1002/humu.20882 19191301
35. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Abifadel M, Rabes JP, Jambart S, Halaby G, Gannage-Yared MH, Sarkis A, Beaino G, Varret M, Salem N, Corbani S, Hum Mutat 2009 30 7 682 E691 10.1002/humu.21002 19319977
36. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K, Circ Cardiovasc Genet 2009 2 4 354 361 10.1161/CIRCGENETICS.108.828467 20031607
37. Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture. Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, Ooi TC, Davignon J, Seidah NG, Mbikay M, Chretien M, Clin Chem 2011 57 10 1415 1423 10.1373/clinchem.2011.165191 21813713
38. My Road to Damascus: How I converted to the Prohormone Theory and the Proprtoein Convertases. Chretien M, Biochem Cell Biol 2012 90 6 750 768 10.1139/o2012-031 23194189
39. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Scartezini M, Hubbart C, Whittall RA, Cooper JA, Neil AH, Humphries SE, Clin Sci (Lond) 2007 113 11 435 441 10.1042/CS20070150 (Pubitemid 350221385)
40. Healthy individuals carrying the PCSK9 p. R46L variant and familial hypercholesterolemia patients carrying PCSK9 p. D374Y exhibit lower plasma concentrations of PCSK9. Humphries SE, Neely RD, Whittall RA, Troutt JS, Konrad RJ, Scartezini M, Li KW, Cooper JA, Acharya J, Neil A, Clin Chem 2009 55 12 2153 2161 10.1373/clinchem.2009.129759 19797716
41. Genetic and metabolic determinants of plasma PCSK9 levels. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH, J Clin Endocrinol Metab 2009 94 7 2537 2543 10.1210/jc.2009-0141 19351729
42. A new method for measurement of total plasma PCSK9: clinical applications. Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, J Lipid Res 2010 51 1 140 149 10.1194/jlr.M900273-JLR200 19571328
43. Lipid Research Clinics Population Studies Data Report; The Prevalence Study. Rifkind B, NIH 1980 1 80 1527